Results 101 to 110 of about 39,808 (354)

Day‐Case Laparoscopic Hysterectomy: A Successful Pilot in Regional New Zealand

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT We conducted a day‐case total laparoscopic hysterectomy service improvement project at Nelson Public Hospital, New Zealand, in August and September, 2024. A retrospective analysis was performed, and a voluntary patient questionnaire administered, at the 4‐week postoperative review.
Ben McLaughlin, Jonathan Panckhurst, Richard Carpenter   +2 more
wiley   +1 more source

Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

Cancer Management and Research, 2018
Toshinobu Hayashi,1,2 Mototsugu Shimokawa,3 Koichi Matsuo,2 Takanori Miyoshi,4 Yoko Toriyama,4 Chiaki Yokota,5 Jun Taniguchi,6 Kiyonori Hanada,7 Kyouichi Tsumagari,8 Noriko Okubo,9 Yoshimichi Koutake,10 Kohei Sakata,11 Yosei Kawamata,12 Takashi Goto,13 ...
Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M   +15 more
doaj  

Assessment of acute headache in adults - what the general physician needs to know. [PDF]

, 2018
Headache is common. Up to 5% of attendances to emergency departments and acute medical units are due to headache. Headache is classified as either primary (eg migraine, cluster headache) or secondary to another cause (eg meningitis, subarachnoid ...
Agrawal, Cappelen-Smith, Dodick, Hoffmann, Mac Grory, Macdonald, omi, Savitz, Sheikh, Solomon   +9 more
core   +1 more source

Same‐Day Discharge Metabolic‐Bariatric Surgery in Australia: Experience in a Regional Public Hospital

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Access to publicly funded bariatric surgery (MBS) remains suboptimal across Australia and New Zealand. The COVID‐19 pandemic placed additional stress on the public healthcare system, and as a result, overnight beds in public hospitals have become a premium commodity.
Lee S. Kyang, Igor Lemech, Richard Harrison, Denbigh Simond, Nicholas Williams   +4 more
wiley   +1 more source

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting [PDF]

, 2018
Background: We assessed adherence to the European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) at our institution.
Aebi, Stefan, Burmeister, Henning, Fey, Martin, Gautschi, Oliver, Studer, Cristina   +4 more
core  

Feasibility and safety of awake craniotomy in adult patients with drug‐resistant focal epilepsy

Epilepsia, EarlyView.
Abstract Objective Although awake craniotomy can guide functional brain mapping and resection, its feasibility and safety have been poorly studied in large series of patients with drug‐resistant focal epilepsy surgery. Methods We conducted an observational, retrospective, single‐center cohort study of 588 consecutive awake craniotomies (2010–2024 ...
Marc Zanello, Gonzague De France, Angela Elia, Marco Demasi, Cristina Filipescu, Elisabeth Landre, Alessandro Moiraghi, Bénédicte Trancart, Maimiti Seneca, Agathe Guibert, Fabrice Chretien, Alexandre Roux, Johan Pallud   +12 more
wiley   +1 more source

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary: This randomized trial was designed to test the effectiveness and safety of rimegepant for the acute treatment of migraine among adults in Japan. Results indicated that rimegepant was more effective than placebo, and the 75 mg dose was observed to be more effective than the 25 mg dose.
Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Robert Croop, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +11 more
wiley   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Adherence to guidelines on prophylaxis of chemotherapy-induced nausea and vomiting in the National Cancer Institute, Sudan

South African Journal of Oncology, 2017
Objective: To evaluate the adherence to American Society of Clinical Oncology (ASCO) guidelines for antiemetic prophylaxis of chemotherapy-induced nausea and vomiting and assess the outcomes of the prescribed antiemetic drugs. Methods: This prospective,
Moawia M.A. Elhassan, Arwa A.S.A. Ali, Mohamed O.M. Elmustafa   +2 more
doaj   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen, Aaron Jenkins, Karin Hygge Blakeman, Feng Dai, Lucy Abraham, Chelsea Leroue, Josh Brown   +6 more
wiley   +1 more source